Cargando…

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?

Endometriosis is a chronic disease, in which endometrial-like tissue is found outside the uterine cavity. Lesions are typically located in the true pelvis but can be found, in addition to extragenital endometriosis, in the respiratory system, the diaphragm, the pleura or the pericardium. As the extr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rzewuska, Anna Maria, Żybowska, Monika, Sajkiewicz, Ilona, Spiechowicz, Izabela, Żak, Klaudia, Abramiuk, Monika, Kułak, Krzysztof, Tarkowski, Rafał
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918258/ https://www.ncbi.nlm.nih.gov/pubmed/36769656 http://dx.doi.org/10.3390/jcm12031008

Ejemplares similares

Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis
por: Abramiuk, Monika, et al.
Publicado: (2023)

Future Perspectives of Ectopic Pregnancy Treatment—Review of Possible Pharmacological Methods
por: Leziak, Milena, et al.
Publicado: (2022)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

The impact of endometriosis on depressive and anxiety symptoms and quality of life: a systematic review
por: Szypłowska, Małgorzata, et al.
Publicado: (2023)

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
por: Pohl, Oliver, et al.
Publicado: (2022)

The Role of the Immune System in the Development of Endometriosis
por: Abramiuk, Monika, et al.
Publicado: (2022)

Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
por: Satora, Małgorzata, et al.
Publicado: (2023)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis
por: Xin, Lingli, et al.
Publicado: (2023)

Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis
por: Resta, Christina, et al.
Publicado: (2023)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

CLTA-4 Expression Is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility
por: Abramiuk, Monika, et al.
Publicado: (2021)

The Neutrophil to Lymphocyte Ratio in Children with Bronchial Asthma
por: Wawryk-Gawda, Ewelina, et al.
Publicado: (2023)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor
por: Fjellaksel, Richard, et al.
Publicado: (2017)

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
por: Chappell, Neil, et al.
Publicado: (2017)

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
por: Liu, Yi-Fu, et al.
Publicado: (2021)

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
por: Osuga, Yutaka, et al.
Publicado: (2021)

CD200 and CD200R Expression on Peripheral Blood Lymphocytes and Serum CD200 Concentration as a New Marker of Endometriosis
por: Abramiuk, Monika, et al.
Publicado: (2020)

Ischemic Stroke in the Course of COVID-19 in a 16-Year-Old Boy
por: Syzdoł, Bartłomiej, et al.
Publicado: (2023)

Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol
por: Park, Chan Woo, et al.
Publicado: (2014)

Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization
por: Kwon, Su-Kyoung, et al.
Publicado: (2013)

Comparative proteomics reveal negative effects of gonadotropin-releasing hormone agonist and antagonist on human endometrium
por: Chen, Qian, et al.
Publicado: (2019)

Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
por: Kawahara, Takashi
Publicado: (2020)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage ‘in mice
por: Levi, Mattan, et al.
Publicado: (2022)

Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist
por: Trudeau, Vance L, et al.
Publicado: (2010)

Luteinizing hormone changes in gonadotropin-releasing hormone antagonist protocol in in vitro fertilization cycles: A cross-sectional study
por: Hosein Rashidi, Batool, et al.
Publicado: (2019)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis
por: Lee, Dong-Yun, et al.
Publicado: (2016)

Rapidly growing extensive polypoid endometriosis after gonadotropin-releasing hormone agonist discontinuation: A case report
por: Zhang, De-Yu, et al.
Publicado: (2023)

Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study
por: Karthik, Sajja Devendra Siva, et al.
Publicado: (2018)

Comparative multiplex analysis of cytokines, chemokines and growth factors in follicular fluid of normoresponder women undergoing ovum donation with gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist protocols
por: Malhotra, Neena, et al.
Publicado: (2013)

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol
por: Chang, Hye Jin, et al.
Publicado: (2009)

The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS
por: Eftekhar, Maryam, et al.
Publicado: (2016)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2017)

Discovery of a Lead Brain‐Penetrating Gonadotropin‐Releasing Hormone Receptor Antagonist with Saturable Binding in Brain
por: Bekker, Roberto B. W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tbsvc7v27iqvr6pg9teju5subh